View Older Stories View More Recent Stories

Oct 10, 2022 08:00AM Merck Recognized on Fortune’s 2022 Change the World List for Expanding Access to HPV Vaccines
Oct 10, 2022 06:46AM Merck (MRK) Reports Positive Top-line Results from Pivotal Phase 3 STELLAR Trial of Sotatercept
Oct 10, 2022 06:45AM Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)
Oct 7, 2022 06:12AM Merck (MRK) and Ridgeback Biotherapeutics Provide Update on New Studies of LAGEVRIO
Oct 6, 2022 07:50PM Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
Oct 4, 2022 04:30AM MilliporeSigma Announces a Boost in Commercial Capacity in France as Part of New Millipore® CTDMO Services
Sep 29, 2022 03:23PM Merck (MRK) Announces U.S. Court of Appeals for Federal Circuit Rules in Favor of it in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
Sep 29, 2022 03:22PM U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
Sep 29, 2022 06:45AM Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27
Sep 27, 2022 07:00AM Merck Animal Health Completes Minority Investment in LeeO Precision Farming
Sep 27, 2022 06:45AM Merck (MRK) KEYTRUDA Granted Four New Approvals in Japan
Sep 27, 2022 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Sep 22, 2022 07:30AM Merck Animal Health (MRK) to Acquire Vence
Sep 22, 2022 07:30AM Merck Animal Health to Acquire Vence
Sep 22, 2022 06:59AM Merck (MRK) Announces Court Ruling in Favor of Merck in Sitagliptin Phosphate Patent Lawsuit
Sep 22, 2022 06:45AM LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
Sep 22, 2022 06:40AM U.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit
Sep 20, 2022 06:46AM Merck (MRK) to Initiate New Phase 3 Trial with Lower Dose of Daily Oral Islatravir with Doravirine for Treatment of People with HIV-1 Infection
Sep 20, 2022 06:45AM Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection
Sep 16, 2022 07:30AM Merck (MRK) Receives Positive CHMP Opinion for VAXNEUVANCE
Sep 16, 2022 07:30AM Merck (MRK) Receives Positive CHMP Opinion for VAXNEUVANCE
Sep 16, 2022 07:30AM Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children
Sep 12, 2022 08:56AM Seagen (SGEN), Merck (MRK) and Astellas Report Results of Trial Investigating PADCEV
Sep 12, 2022 08:55AM Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urotheli
Sep 12, 2022 08:55AM Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urotheli
Sep 12, 2022 05:42AM Merck (MRK) Announces Strong Five-Year Data for KEYTRUDA Plus Chemotherapy in NSCLC
Sep 12, 2022 05:26AM Merck (MRK) and Eisai Report Results From Phase 3 LEAP-002 Trial of KEYTRUDA Plus LENVIMA
Sep 11, 2022 04:15AM Five-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)
Sep 10, 2022 02:30AM Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Ca
Sep 9, 2022 08:01AM Merck (MRK) Announces LYNPARZA in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in
Sep 9, 2022 08:00AM LYNPARZA® (olaparib) in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Explorat
Sep 8, 2022 09:00AM MilliporeSigma Announces Investment of More Than € 130 Million to Strengthen Manufacturing Capabilities in Molsheim, France
Sep 6, 2022 06:45AM Merck to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Aug 30, 2022 04:01PM Merck Reports Strong Progress in ESG Focus Areas
Aug 29, 2022 06:45AM Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer
Aug 25, 2022 06:46AM Merck (MRK) and AstraZeneca (AZN) Announces LYNPARZA Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
Aug 25, 2022 06:45AM LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
Aug 23, 2022 06:46AM Merck (MRK) Granted FDA Fast Track Designation for MK-2060
Aug 23, 2022 06:45AM Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy
Aug 16, 2022 07:10AM AstraZeneca (AZN). Merck (MRK) Annound FDA Accepts Submission of sNDA for LYNPARZA in Combination With Abiraterone and Prednisone or Prednisolone for Patients with mCRPC
Aug 16, 2022 07:00AM FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant P
Aug 16, 2022 06:47AM Merck (MRK) Enters Deal with Orna Therapeutics to Develop RNA Technology
Aug 16, 2022 06:45AM Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
Aug 9, 2022 08:00AM MilliporeSigma Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform
Aug 4, 2022 06:45AM LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
Aug 3, 2022 06:45AM Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carci
Aug 3, 2022 06:42AM Merck (MRK) Announces Phase 3 KEYNOTE-921 Trial Did Not Meet Endpoints
Aug 3, 2022 06:40AM Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Jul 28, 2022 06:30AM Merck Announces Second-Quarter 2022 Financial Results
Jul 26, 2022 12:40PM Merck Announces Fourth-Quarter 2022 Dividend
View More Recent Stories View Older Stories